Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DYN vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DYN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

DYN Overall Winner 6-Pillar Tally: DYN 2 – 2 MESO (2 Tie) Matrix Metrics: DYN 6 – 2 MESO

As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). DYN carries a Unified Composite Score of 47.5/100 (HOLD) at $16.68 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: DYN earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. MESO 35.5/100 SELL) and 1.73β · 59% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DYN vs MESO
DYN NASDAQ Head-to-Head Winner
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$16.68
-2.8% 1D
Market Cap $3.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.73β · 59% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -17.2%) with fading momentum, RSI 46
RSI-14: 45.9 · SMA20: $17.09 · SMA50: $16.81
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (DYN 2 – 2 MESO)

Columns: Metric · DYN · MESO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.19x N/M
EV / Revenue N/M 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +0.0% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $120M
Market Cap $3.2B $1.7B
3. Profitability & Quality DYN
Gross Margin N/A 80.0%
Operating Margin 0.0% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -74.6% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$569M -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $694M Net Cash $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DYN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 124.9% (25th %ile) 76.8% (37th %ile)
Put/Call OI Skew 0.10x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DYN (6) vs MESO (2)
Institutional Metric DYN MESO Criterion Row Edge
Market Capitalization
Scale
$3.2B $1.7B Larger Scale DYN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
0.0% -42.6% Higher Margin DYN
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin DYN
Return on Equity (ROE)
Capital Efficiency
-74.6% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
20% ($14–$27) 6% ($12–$22) Stronger Trend DYN
Beta / 30D Volatility
Risk Regime
1.73β · 59% Vol 1.18β · 78% Vol Lower Realized Risk DYN
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite DYN
Trailing 12M Revenue (USD)
Operating Scale
N/A $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.19x PEG · N/M EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$569M ($694M Net Cash) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DYN +23.15 pp
DYN: +17.05% · MESO: -6.1%
3M Horizon MESO +10.66 pp
DYN: -35.85% · MESO: -25.19%
6M Horizon DYN +15.67 pp
DYN: +0.85% · MESO: -14.82%
1Y Horizon DYN +5.0 pp
DYN: -11.42% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs MESO. Trailing 12-month operating profitability (DYN 0.0% vs MESO -42.6%) and valuation multiples (DYN N/M vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DYN BREAKDOWN
68d in phase · OBV ACCUMULATION
Current IV 124.9%
IV Percentile 25th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DYN vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). DYN carries a Unified Composite Score of 47.5/100 (HOLD) at $16.68 (N/M Forward P/E, 0.0% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: DYN earns the overall head-to-head edge with a stronger Unified Composite Score (47.5/100 HOLD vs. MESO 35.5/100 SELL) and 1.73β · 59% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: DYN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, DYN generates N/A in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, DYN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

DYN and MESO trade at balanced relative valuation multiples. DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DYN (-74.6% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, DYN carries 124.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 59% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.